债券代码：123119 债券简称：康泰转 2 证券代码：300601 证券简称：康泰生物 公告编号：2023-057 深圳康泰生物制品股份有限公司 关于 2023 年半年度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 深圳康泰生物制品股份有限公司（以下简称"公司"）于2023年8月25日召 开第七届董事会第十二次会议、第七届监事会第十次会议，审议通过了《关于2023 年半年度计提资产减值准备的议案》。根据《深圳证券交易所创业板股票上市规 则》、《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范 运作》等相关法律法规的规定，现将相关情况公告如下： 为了更加真实、准确地反映公司资产状况和财务状况，根据《企业会计准 则》及公司会计政策的相关规定，公司对合并报表范围内截至2023年6月30日的 各类资产进行了全面清查，对各项资产进行了充分的分析、测试和评估，根据 减值测试结果，本着谨慎性的原则，公司对存在减值迹象的相关资产计提减值 准备。 （二）本次计提资产减值准备的范围和金额 公司对存在减值迹象的资产进行计提资产减值准备，20 ...

深圳康泰生物制品股份有限公司（以下简称"公司"）第七届监事会第十次 会议通知于2023年8月15日以书面及通讯方式通知了全体监事，会议于2023年8 月25日在公司会议室以现场表决和通讯表决相结合的方式召开。会议由监事会主 席吕志云先生召集并主持，本次会议应参加表决监事3名，实际参加表决监事3 名。本次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件和 《公司章程》的有关规定。 经过全体监事认真审议，会议通过了相关议案并形成如下决议： 一、审议通过了《关于公司2023年半年度报告及摘要的议案》，表决结果： 3票同意、0票反对、0票弃权。 经审核，监事会认为：董事会编制和审核公司 2023 年半年度报告及摘要的 程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反 映了公司的实际情况，不存在任何虚假记载、误导性陈述或重大遗漏。 《2023 年半年度报告》《2023 年半年度报告摘要》的具体内容详见公司同日 在巨潮资讯网（http://www.cninfo.com.cn）披露的公告。 二、审议通过了《关于2023年半年度利润分配预案的议案》，表决结果：3 票同意、0票反对、0票弃权。 ...

深圳康泰生物制品股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 根据《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要 求》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运 作》及《深圳证券交易所创业板上市公司自律监管指南第1号——业务办理》等 规定，现将深圳康泰生物制品股份有限公司（以下简称"公司"）2023年半年度 募集资金存放与使用情况专项报告如下： 证券代码：300601 证券简称：康泰生物 公告编号：2023-056 债券代码：123119 债券简称：康泰转 2 一、募集资金基本情况 （一）公开发行可转换公司债券募集资金基本情况 1.实际募集资金金额、资金到位情况 经中国证券监督管理委员会《关于核准深圳康泰生物制品股份有限公司公开 发行可转换公司债券的批复》（证监许可[2018]42 号）核准，公司于 2018 年 2 月 1 日公开发行 356 万张可转换公司债券，发行价格为每张 100 元，募集资金总 额为人民币 35,600 万元，扣除承销费、保荐费 ...

中信建投证券股份有限公司 一、保荐工作概述 2023 年上半年度跟踪报告 | 保荐机构名称：中信建投证券股份有限公司 | 被保荐公司简称：康泰生物 | | --- | --- | | 保荐代表人姓名：龙舟（2021 年向不特定对象 | 联系电话：010-86451658 | | 发行可转债） | | | 保荐代表人姓名：宋双喜（2021 年向不特定对 年非公开发行股票、2018 | 联系电话：010-85130683 | | 象发行可转债、2020 | | | 年公开发行可转债） | | | 年非公开发行 保荐代表人姓名：隋玉瑶（2020 | 联系电话：010-85130265 | | 股票、2018 年公开发行可转债） | | | 项 目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2．督导公司建立健全并有效执行规章制度的 | | | 情况 | | | （1）是否督导公司建立健全规章制度（包括 | | | 但不限于防止关联方占用公司资源的制度、募 | 是 ...

| 证券代码：300601 | 证券简称：康泰生物 | 公告编号：2023-055 | | --- | --- | --- | | 债券代码：123119 | 债券简称：康泰转 2 | | 债券代码：123119 债券简称：康泰转 2 深圳康泰生物制品股份有限公司 为积极回报股东，与股东分享公司经营发展的成果，结合公司的实际情况， 在保障公司正常经营和长远发展的前提下，公司董事会拟定2023年半年度利润分 配预案为：拟以2023年半年度权益分派实施公告中确定的股权登记日当日的总股 本为基数，以未分配利润向全体股东每10股派1.80元（含税）现金红利，不送红 股，不以资本公积金转增股本。 二、董事会意见 关于 2023 年半年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 深圳康泰生物制品股份有限公司（以下简称"公司"）于2023年8月25日召 开第七届董事会第十二次会议、第七届监事会第十次会议，会议审议通过了《关 于2023年半年度利润分配预案的议案》，具体情况如下： 一、2023年半年度利润分配预案基本情况 根据公司2023年半年度财务 ...

证券代码：300601 证券简称：康泰生物 债券代码：123119 债券简称：康泰转 2 深圳康泰生物制品股份有限公司 投资者关系活动记录表 编号：2023-004 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 投资者关系 □新闻发布会 □路演活动 活动类别 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称 及人员姓名 线上参与康泰生物 2022 年度网上业绩说明会的投资者 时间 2023 年 05 月 05 日（星期五）下午 15:00-17:00 地点 "康泰生物投资者关系"微信小程序 董事、总裁：苗向先生 独立董事：李皎予先生 上市公司接待 财务总监：周慧女士 人员姓名 董事会秘书：陶瑾女士 保荐代表人：龙舟先生 公司于 2023 年 5 月 5 日（星期五）15:00-17:00 在"康泰生物投 资者关系"微信小程序通过网络远程的方式举行 2022 年度网上业 绩说明会，就投资者关注的问题进行了回复。本次交流的主要内 容如下： 投资者关系活动 Q1：公司狂苗审批遇到了什么问题呢？五联苗为什么还没进入一 主要内容介绍 期临床？ A1：您好，公司冻干人用狂犬病疫苗（人二倍体细胞）4 ...

Financial Performance - The company's revenue for Q1 2023 was ¥748,383,301.39, a decrease of 14.12% compared to ¥871,425,498.86 in the same period last year[3] - Net profit attributable to shareholders was ¥205,462,820.25, down 24.90% from ¥273,588,319.57 year-on-year[3] - Basic earnings per share decreased by 55.00% to ¥0.18 from ¥0.40 in the previous year[3] - Total operating revenue decreased to ¥748,383,301.39 from ¥871,425,498.86, representing a decline of approximately 14.1% year-over-year[23] - Net profit for the period was ¥205,462,820.25, down from ¥273,588,319.57, indicating a decrease of about 25%[24] - Operating profit fell to ¥244,347,202.88 from ¥327,201,104.05, a decline of approximately 25.3%[23] - Total operating costs decreased to ¥502,644,829.28 from ¥561,389,213.81, a reduction of about 10.4%[23] - Other income decreased to ¥19,563,457.11 from ¥34,787,977.53, a decline of approximately 43.8%[23] - Tax expenses were ¥4,170,169.45, slightly down from ¥4,409,467.96, indicating a decrease of about 5.4%[23] Cash Flow and Assets - The net cash flow from operating activities was ¥128,596,484.59, a significant increase of 312.07% compared to a negative cash flow of -¥60,639,409.79 in the same period last year[10] - The company’s cash and cash equivalents decreased by 87.38% to -¥64,353,969.53 compared to -¥510,105,564.10 in the same period last year[10] - The company’s cash and cash equivalents at the end of the period were RMB 953,006,393.21, down from RMB 1,017,621,857.91 at the beginning of the year, representing a decrease of approximately 6.36%[20] - Total cash outflow from operating activities amounted to $513.99 million, compared to $873.65 million in the prior period[26] - Cash inflow from investment activities reached $434.55 million, a substantial increase from $63.05 million in the previous period[26] - The ending balance of cash and cash equivalents was $929.76 million, down from $3.01 billion at the end of the previous period[26] Shareholder Information - The company reported a total of 201,730,680 shares held by major shareholder Yuan Liping, representing 18.06% of total shares[12] - The company has a total of 213,581,357 restricted shares held by executive Du Weimin, with 416,925 shares added this period[13] - The company has a total of 235,537,028 restricted shares held by executives, with 1,020,518 shares added this period[14] - The company has a significant shareholder structure, with the top 10 shareholders holding a combined total of 364,000,000 shares[12] - The company’s board members and senior management collectively increased their shareholding by 1,375,691 shares, with a total investment of RMB 5,049.67 million[18] Urban Renewal Project - The company is progressing with its urban renewal project, having completed the main structure and is currently conducting final acceptance work[16] - The urban renewal project includes a compensation agreement for 22,348 square meters of research and development space and cash compensation of RMB 60 million[16] - The company has received all necessary permits for the urban renewal project, including land use and construction permits[16] - The company plans to transform its industrial park into a significant research and headquarters center for the biopharmaceutical industry[15] - The company is focused on expanding its market presence through urban renewal and enhancing its biopharmaceutical capabilities[15] - The company has established a strategic partnership with Shenzhen's urban planning authorities to facilitate its urban renewal initiatives[15] Financial Management - The company reported a significant decrease in financial expenses by 68.88% to -¥2,284,276.70 due to reduced interest income from deposits[9] - The company’s total equity attributable to shareholders increased by 1.16% to ¥9,089,852,318.77 from ¥8,985,338,168.88 at the end of the previous year[3] - Total liabilities decreased to RMB 4,714,789,335.50 from RMB 4,801,013,502.27, reflecting a decrease of approximately 1.80%[21] Miscellaneous - The company did not conduct an audit for the first quarter report[28] - The first quarter report was released on April 24, 2023[28]

Financial Performance - The company's sales revenue from routine vaccines (excluding COVID-19 vaccines) reached CNY 2,945.63 million, representing a year-on-year growth of 85.39%[3]. - The company's revenue for 2022 was approximately ¥3.16 billion, a decrease of 13.55% compared to ¥3.65 billion in 2021[16]. - The net profit attributable to shareholders was approximately -¥132.71 million, representing a decline of 110.50% from ¥1.26 billion in the previous year[16]. - The company's total operating revenue for 2022 was approximately ¥3.16 billion, a decrease of 13.5% from ¥3.65 billion in 2021[17]. - The company reported a net profit of -¥182.75 million, a decrease of 115.35% from ¥1.19 billion in 2021[16]. - The net cash flow from operating activities decreased by 66.97% to approximately ¥545.70 million, down from ¥1.65 billion in 2021[16]. - Basic earnings per share were -¥0.12, a drop of 106.49% compared to ¥1.85 in 2021[16]. - The weighted average return on net assets was -1.44%, a decline of 16.49% from 15.05% in the previous year[16]. - The company's total operating costs decreased by 49.32% to CNY 499,947,447.95 in 2022 from CNY 986,428,002.39 in 2021[59]. - The company achieved a gross margin of 84.59% for biological products, which is a decrease of 11.58% compared to the previous year[56]. Vaccine Sales and Market Trends - Sales revenue from the tetravalent vaccine increased by 54.18% compared to the previous year, while hepatitis B vaccine sales grew by 26.34%[3]. - The company experienced a significant decline in COVID-19 vaccine sales compared to last year, leading to a loss in 2022 due to asset impairment provisions related to COVID-19 vaccine assets[3]. - The global vaccine market is projected to grow from approximately $46 billion in 2021 to about $83.1 billion by 2025, with a compound annual growth rate (CAGR) of 13.5%[23]. - China's vaccine market is expected to reach approximately ¥383.5 billion by 2031, with a CAGR of 15.95% from 2020 to 2031[23]. - The company reported a significant decline in COVID-19 vaccine sales, which impacted overall performance during the reporting period[36]. - The domestic adult vaccine market is anticipated to expand significantly due to increasing awareness and demand for vaccines among the aging population[26]. Research and Development - The company is focusing on the development of multi-valent vaccines and expanding its market presence[10]. - The company has plans for new product development and technological advancements in the vaccine sector[10]. - The company has over 30 ongoing research projects, including new vaccines such as the 20-valent pneumococcal conjugate vaccine and recombinant zoster vaccine, which are expected to enhance its product offerings[31]. - The company has established five R&D and production bases in Shenzhen and Beijing, positioning itself as a leading player in the domestic vaccine industry[30]. - The company has completed registration site verification and GMP compliance checks for its self-developed freeze-dried human rabies vaccine[37]. - The company is developing multiple new vaccines, including a quadrivalent hand-foot-mouth disease vaccine and a recombinant respiratory syncytial virus vaccine, which will support future growth[37]. - The company has initiated clinical trials for multiple vaccines, including the recombinant enterovirus 71 vaccine and the combined vaccine for diphtheria, tetanus, and pertussis, indicating a robust pipeline for future growth[43]. - The company has established multiple advanced research platforms, including the "Guangdong Province Therapeutic Hepatitis B Vaccine Engineering Laboratory" and "Shenzhen New Vaccine Engineering Laboratory," enhancing its R&D capabilities[48]. International Expansion and Collaborations - The company is committed to international collaboration, having partnered with global leaders like Merck and Sanofi Pasteur to enhance its vaccine technology[31]. - The company has established partnerships in the Philippines and Indonesia to promote the registration and distribution of its 13-valent and 23-valent pneumococcal vaccines[39]. - The company has signed a strategic cooperation memorandum with AstraZeneca and Combiphar for local production and commercialization of vaccines in Indonesia, indicating a strong market expansion strategy[40]. - The company has established international collaborations for vaccine registration and distribution in countries like the Philippines, Indonesia, and Pakistan[51]. - The company plans to continue expanding its international market presence and diversify sales channels for its products[51]. Quality Management and Compliance - The company emphasizes quality management, adhering to strict regulations to ensure the safety and effectiveness of its vaccine products[38]. - The company is focused on maintaining high-quality vaccine production to mitigate risks related to adverse vaccination events[99]. - The company has a strong commitment to quality management, achieving compliance declarations from international authorities for its production facilities, aligning its quality management system with international standards[49]. - The internal control audit report confirmed the effectiveness of the internal control system as of December 31, 2022, with a standard unqualified opinion issued[156]. Corporate Governance and Shareholder Relations - The company has established a complete independent financial system, with dedicated financial personnel and independent financial decision-making processes[118]. - The board of directors consists of 8 members, including 3 independent directors, ensuring compliance with governance standards[108]. - The company emphasizes the protection of stakeholders' rights, actively engaging with shareholders, employees, customers, and suppliers[113]. - The company has a dedicated investor relations management system, ensuring effective communication with investors through various channels[112]. - The company held 6 board meetings during the reporting period, all convened and chaired by the chairman, complying with legal and regulatory requirements[108]. Environmental Responsibility - The total investment in environmental governance and protection during the reporting period amounted to RMB 4.2459 million, including RMB 1.0110 million in environmental protection tax[169]. - The company has installed online monitoring systems for wastewater treatment, tracking COD, ammonia nitrogen, pH, and flow in real-time, ensuring compliance with environmental standards[168]. - The company actively supports poverty alleviation and rural revitalization, donating RMB 1.5 million to welfare projects in Jiangxi Province since 2018[172]. - The company has committed to energy-saving measures, including the use of variable frequency technology and intelligent control systems, to reduce energy waste[170]. Future Outlook and Strategic Initiatives - The company plans to continue expanding its market presence and investing in new product development[126]. - Future guidance suggests a revenue growth target of 10% for the next fiscal year, driven by new product launches and market expansion efforts[131]. - The company aims to advance key product development, focusing on rabies vaccine, varicella vaccine, and inactivated polio vaccine registration processes in 2023[90]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[131]. - The management emphasized the importance of maintaining high-quality standards in product development to ensure customer satisfaction and regulatory compliance[131].

证券代码：300601 证券简称：康泰生物 公告编号：2023-041 深圳康泰生物制品股份有限公司 债券代码：123119 债券简称：康泰转 2 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 投资者依据提示，授权登入"康泰生物投资者关系"小程序，即可参与交流。 出席本次业绩说明会的人员有：公司董事、总裁苗向先生，独立董事李皎予 先生，财务总监周慧女士，董事会秘书陶瑾女士，保荐代表人龙舟先生。 欢迎广大投资者积极参与本次业绩说明会。 深圳康泰生物制品股份有限公司（以下简称"公司"）于 2023 年 4 月 24 日 在巨潮资讯网（http://www.cninfo.com.cn)披露了《2022 年年度报告》及其摘 要。为使投资者能够进一步了解公司发展战略、经营管理等情况，公司将于 2023 年 5 月 5 日（星期五）15:00-17:00 在"康泰生物投资者关系"小程序举办 2022 年度网上业绩说明会，本次年度业绩说明会将采用网络远程的方式举行，投资者 可登陆"康泰生物投资者关系"小程序参与互动交流。为广泛 ...